Ligand ID: CYZ


Drugbank ID:
DB00606
(Cyclothiazide)


Indication:
Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Get human targets for CYZ in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'CYZ' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		4 / 5
ILE D 931
SER D 937
LYS D 933
GLY D 932
1.59A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 10
SER A 975
LEU B 977
LEU A1166
ASP A1165
ILE C 980
1.74A8.38
None
None
None
ZN  A1304 (-2.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.54A22.02

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.54A22.02

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.43A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.46A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.68A12.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_1
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
PRO C1053
SER C1055
LEU C 806
SER C 816
ASP C 820
1.79A12.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE A 931
SER A 937
LYS A 933
GLY A 932
1.42A12.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.43A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ILE A 434
SER A 375
SER A 438
LEU A 368
SER A 373
1.43A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.45A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ILE A 434
SER A 375
SER A 438
LEU A 368
SER A 373
1.43A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.46A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.60A12.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.44A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU C1063
LEU C 806
ASP C 808
ILE C 934
GLY C 932
1.59A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
SER A 438
LEU A 368
SER A 373
ILE A 434
SER A 375
1.44A22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
PRO B1053
SER B1055
LEU B 806
SER B 816
ASP B 820
1.74A12.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE B 931
SER B 937
LYS B 933
GLY B 932
1.62A13.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ILE B 231
LEU B 117
SER B 116
LEU B 110
ASP B 111
1.46A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU C 117
SER C 116
LEU C 110
ASP C 111
ILE C 231
1.46A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 117
SER A 116
LEU A 110
ASP A 111
ILE A 231
1.46A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU C1063
LEU C 822
LYS C 825
ILE C 931
GLY C 932
1.57A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU A 117
SER A 116
LEU A 110
ASP A 111
ILE A 231
1.45A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
ILE B 231
LEU B 117
SER B 116
LEU B 110
ASP B 111
1.45A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
LEU B1063
LEU B 822
LYS B 825
ILE B 931
GLY B 932
1.51A22.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3TKD_A_CYZA266_2
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 5
ILE A 931
SER A 937
LYS A 933
GLY A 932
1.59A13.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_B_CYZB329_1
(GLUTAMINE RECEPTOR 2)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		5 / 9
LYS B 143
PRO B 142
SER A 105
LEU A 104
ASP A 103
1.78A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LYS A 159
PRO A 158
SER A 198
ILE A 169
SER A 162
1.71A22.40
EDO  A 413 (-4.5A)
EDO  A 413 (-4.6A)
None
EDO  A 403 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LYS A 159
PRO A 158
SER A 198
ILE A 169
SER A 162
1.72A22.40
EDO  A 413 (-4.5A)
EDO  A 413 (-4.6A)
None
EDO  A 403 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6w61 NSP10
(SARS-CoV-2)		5 / 11
ILE B4291
SER B4325
PRO B4360
LEU B4328
LEU B4345
1.61A8.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6w61 NSP10
(SARS-CoV-2)		5 / 11
ILE B4291
SER B4325
PRO B4360
LEU B4328
LEU B4345
1.61A8.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LYS B 163
LEU B 164
LEU B  10
LYS A  19
ILE B 137
1.76A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_C_CYZC265_1
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		5 / 11
ILE B 137
LYS B 163
LEU B 164
LEU B  10
LYS A  19
1.74A19.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6w75 NSP16
(SARS-CoV-2)		5 / 10
SER C7041
LEU C7037
LEU C6834
ILE C7035
GLY C6806
1.79A9.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
ILE B 107
SER A  57
SER A  61
LEU B  95
LEU A  55
1.75A8.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 10
SER A  61
LEU B  95
LEU A  55
ILE B 107
SER A  57
1.74A6.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
SER C7041
LEU C7037
LEU C6834
ILE C7035
GLY C6806
1.79A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wkq NSP16
(SARS-CoV-2)		5 / 10
SER C7041
LEU C7037
LEU C6834
ILE C7035
GLY C6806
1.79A14.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_C_CYZC265_1
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE B 169
SER B 162
LYS B 159
PRO B 158
SER B 198
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LYS B 159
PRO B 158
SER B 198
ILE B 169
SER B 162
1.70A22.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LYS B 159
PRO B 158
SER B 198
ILE B 169
SER B 162
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_A_CYZA265_1
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LYS A 159
PRO A 158
SER A 198
ILE A 169
SER A 162
1.69A
None
None
None
None
EDO  A 408 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3H6T_C_CYZC265_1
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
ILE A 169
SER A 162
LYS A 159
PRO A 158
SER A 198
1.77A
None
EDO  A 408 ( 3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_C_CYZC331_1
(GLUTAMINE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE A 169
SER A 162
LYS A 159
PRO A 158
SER A 198
1.73A22.88
None
EDO  A 408 ( 3.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_A_CYZA330_1
(GLUTAMINE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
LYS A 159
PRO A 158
SER A 198
ILE A 169
SER A 162
1.69A22.88
None
None
None
None
EDO  A 408 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1LBC_C_CYZC331_1
(GLUTAMINE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
ILE B 169
SER B 162
LYS B 159
PRO B 158
SER B 198
1.73A22.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
SER A  61
LEU B  95
LEU A  55
ILE B 107
SER A  57
1.79A6.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
SER C  61
LEU D  95
LEU C  55
ILE D 107
SER C  57
1.75A6.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 10
ILE D 107
SER C  57
SER C  61
LEU D  95
LEU C  55
1.76A8.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
SER B 254
GLY B 251
LEU B 242
LEU B 262
ASP B 263
1.74A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM0_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 10
LEU B 242
LEU B 262
ASP B 263
SER B 254
GLY B 251
1.74A14.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
SER A  61
LEU B  95
LEU A  55
ILE B 107
SER A  57
1.77A5.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
ILE D 107
SER C  57
SER C  61
LEU D  95
LEU C  55
1.77A7.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
SER C  61
LEU D  95
LEU C  55
ILE D 107
SER C  57
1.77A5.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 10
ILE B 107
SER A  57
SER A  61
LEU B  95
LEU A  55
1.78A7.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7btf NSP7
NSP8
(SARS-CoV-2)		5 / 10
SER C  61
LEU D  95
LEU C  55
ILE D 107
SER C  57
1.76A6.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7btf NSP7
NSP8
(SARS-CoV-2)		5 / 10
ILE D 107
SER C  57
SER C  61
LEU D  95
LEU C  55
1.77A11.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_B_CYZB1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 10
SER C  61
LEU D  95
LEU C  55
ILE D 107
SER C  57
1.71A6.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 10
ILE D 107
SER C  57
SER C  61
LEU D  95
LEU C  55
1.72A11.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_C_CYZC1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv2 NSP12
(SARS-CoV-2)		5 / 9
ILE A 307
SER A 664
LEU A 636
SER A 635
ASP A 684
1.77A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM1_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DM2_A_CYZA1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv2 NSP12
(SARS-CoV-2)		5 / 9
SER A 664
LEU A 636
SER A 635
ASP A 684
ILE A 307
1.77A21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6DLZ_D_CYZD1302_0
(GLUTAMATE RECEPTOR
2,VOLTAGE-DEPENDENT
CALCIUM CHANNEL
GAMMA-2 SUBUNIT)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
ILE A 536
PRO A 537
PRO A 378
MET A 380
LEU B  91
1.57A
None